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ABSTRACT 
Conventional diagnostic procedures failed to 
provide a definitive diagnosis in a 15 year-old 
girl presenting with severe hirsutism, oligo-
menorrhea, and markedly elevated serum testos-
terone levels. To examine whether androgen 
overproduction was luteinizing hormone (LH) 
dependent and thus likely of ovarian origin we 
performed a new test to suppress LH secretion 
based on the use of Cetrorelix, a short-acting 
gonadotropin-releasing hormone antagonist. 
Subcutaneous administration of Cetrorelix 250 
μg once daily for 5 days resulted in partial 
suppression of serum LH and testosterone. The 
same dose administered twice daily for 5 days 
almost completely suppressed serum LH and 
testosterone, thereby supporting a diagnosis of 
ovarian androgen excess. This observation was 
confirmed by a positive human chorionic 
gonadotropin stimulation test and an MRI 
showing bilateral polycystic ovaries. 
Conclusion: The Cetrorelix suppression test 
appears to be a promising instrument to help 
solve the differential diagnosis of severe hyper-
androgenism in adolescence. 
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INTRODUCTION 
Clinical evaluation, a standardized hormone 
analysis and pelvic ultrasound are usually sufficient 
to provide a definitive diagnosis in most women 
presenting with hirsutism, and oligo- or amenor-
rhea. In 80-90% of cases this work-up will lead to a 
diagnosis of polycystic ovary syndrome (PCOS)1'2. 
If serum total testosterone is higher than 5 nmol/1 
rare causes of androgen excess, such as non-classic 
adrenal enzymatic deficiencies, hyperthecosis, and 
adrenal or ovarian tumors, should be considered3"4. 
This differential diagnosis requires an extensive 
diagnostic work-up that will be necessary in about 
5% of patients presenting with androgen excess. 
Androgen-producing tumors are very rare and occur 
in about one of 500 female patients presenting with 
signs and symptoms of androgen excess. The 
majority will be of ovarian origin. Some virilizing 
ovarian tumors are extremely difficult to localize 
because of their small size5. 
After exclusion of ovarian abnormalities by 
abdominal or transvaginal ultrasound a search for 
adrenal causes is required. This comprises a dexa-
methasone suppression test, an adrenocorticotropin 
(ACTH) stimulation test, and computed tomo-
graphy3. If this does not produce a definitive 
diagnosis, l3lI-cholesterol scintigraphy may be 
helpful in some cases6 7. Venous sampling of the 
ovaries and adrenals is usually a last resort option. 
It is an invasive procedure that even in experienced 
hands may remain inconclusive in 50% of cases, 
and in 5% is associated with complications such as 
infarction or bleeding8. In adolescent girls the 
failure and complication rates may be even higher 
due to technical difficulties related to the small size 
of adrenal and ovarian veins. 
We describe a new test to suppress luteinizing 
hormone (LH) secretion which may be useful to 
localize the source of androgen overproduction in 
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adolescent females with marked androgen excess. 
The test is based on the use of Cetrorelix, a short-
acting gonadotropin-releasing hormone (GnRH) 
receptor antagonist that suppresses LH secretion by 
blocking the pituitary GnRH receptor. 
PATIENT REPORT 
A 15 year-old girl presented with progressive 
hirsutism of recent onset. Menarche was at the age 
of 11 years, followed by a regular menstrual cycle 
for the first year. Thereafter, oligomenorrhea and 
hirsutism developed. Treatment with Diane35® 
(ethinyl estradiol 35 μg + cyproterone acetate 2 mg) 
produced a regular menstrual cycle, but hirsutism 
worsened progressively and eventually she needed 
to shave every other day. Body weight increased by 
15-20 kg during this period. The patient's family 
history was negative for hirsutism. At presentation 
body height was 1.71 m, body weight 107 kg, body 
mass index (BMI) 36.5 kg/m2, blood pressure 
160/90 mm Hg, and waist circumference 106 cm. 
Hair growth was increased on the face, neck, lower 
abdomen and back and on the upper legs with a 
Ferriman-Gallwey score of 15 (normal <8). Acne 
was present on the face and the upper back. There 
was no clitoromegaly, nor signs indicative for 
Cushing's syndrome. Breast development was 
normal. Pending further analysis Diane35 was dis-
continued. Since then she remained amenorrheic. 
An extensive hormone analysis was performed 
from blood samples drawn between 08.00 and 
10.00 h. Total testosterone was markedly elevated 
(8.0 nmol/1, normal range [NR] 0.2-2.9 nmol/1), 
whereas androstenedione (9.8 nmol/1, NR: 1.9-14.4 
nmol/1), dehydroepiandrosterone (DHEA) (44 
nmol/1, NR: 15-45 nmol/1), dehydroepiandrosterone 
sulfate (DHEAS) (7.7 nmol/1, NR: 4.0-10.0 nmol/1), 
17-OH-progesterone (9.1 nmol/1, NR: 3.3-11.1 
nmol/1), serum albumin and sex hormone binding 
globulin (30 nmol/1, NR: 18-114 nmol/1) were 
within the normal range. Serum estradiol was 169 
pmol/1, with LH and follicle stimulating hormone 
(FSH) values of 9.3 U/l and 3.5 U/l, respectively. 
Morning Cortisol was 0.65 μιηοΐ/ΐ and ACTH 28 
ng/1. Urinary Cortisol excretion was 64 nmol/24 h 
(NR: 30-150 nmol/24 h). A 5-day dexamethasone 
suppression test (1 mg tid, for 5 days) reduced 
reduced morning C o r t i s o l to 0.02 μιτιοΐ/ΐ without 
affecting serum androgens. Stimulation with ACTH 
(250 μg intravenously) produced a mild increase of 
17-OH-progesterone from 5.8 nmol/1 to 13.5 nmol/1 
(normal response <43 nmol/1). Marked abdominal 
obesity impaired ultrasound imaging. The ovaries 
appeared to be normal on transrectal ultrasono-
graphy, but again the imaging was poor. Computed 
tomography scan showed normal adrenals; the 
ovaries could not be identified. mI-Norcholesterol 
imaging did not reveal increased uptake. To obtain 
evidence regarding the site of androgen production 
it was decided to suppress LH secretion by way of 
Cetrorelix, a short-acting luteinizing hormone 
releasing hormone (LHRH) antagonist. Cetrorelix 
is licensed to prevent premature LH surges in 
women undergoing controlled ovarian stimulation 
(COH)9'10. It competitively blocks the binding of 
LHRH to its receptor, which causes a dose 
dependent suppression of LH and FSH release. 
After permission from the patient and her 
parents, the Cetrorelix suppression test was per-
formed. Cetrorelix 250 μg was administered sub-
cutaneously once daily at 09.00 h for 5 days. Blood 
samples were taken at 08.30 h, 12.00 h and 16.00 h 
on the first day and at 08.30 h and 16.00 h on 
subsequent days. As shown in the left column of 
Figure 1, serum LH decreased from 11.1 U/l to 4.5 
U/l within 8 hours but returned to its pre-test level 
12 hours later. This pattern of short-term suppres-
sion followed by a partial escape several hours later 
was repeated during the next days. Suppression of 
serum testosterone was also incomplete, showing a 
saw-toothed pattern comparable to that of LH, with 
the exception that the nadir testosterone levels 
gradually decreased from 6.8 nmol/1 on the first day 
to 4.8 nmol/1 on the fifth day. To achieve more 
convincing evidence of LH dependency the test was 
repeated three weeks later with Cetrorelix 250 μg 
twice a day, administered at 09.00 h and 21.00 h. 
Blood sampling was started at 08.00 h and repeated 
every four hours during the first day. As shown in 
the right column of Figure 1, this improved LH 
suppression. Serum LH decreased from 12.8 U/l to 
1.8 U/l within the first 20 hours, but then rose to 
4-5 U/l and remained around this level during the 
following days. The LH escape was not as evident 
as during the once daily injection. Serum testoste-
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Fig. 1: Response to Cetrorel ix 250 μβ subcutaneously, once a day (left co lumn) and twice a day (right column) . The dashed lines 
represent the upper normal limit for serum testosterone in women, and the upper normal estradiol limit in pos tmenopausa l 
women, respectively. 
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rone decreased rapidly from 7.6 to 4.3 nmol/1 
during the first 24 hours, but then needed three days 
to reach its nadir of 3.6 nmol/1. Serum estradiol 
decreased to levels approaching postmenopausal 
values. Confirmation of LH dependency of testos-
terone production was obtained by performing an 
in-hospital dexamethasone/human chorionic gonado-
tropin test (Dex/HCG). Dexamethasone 0.5 mg was 
given every six hours for 7 days, and on the final 
three days this was combined with HCG 1,500 IU 
daily. Dexamethasone alone suppressed serum 
ACTH and Cortisol to a value below the detection 
limit but did not affect serum androgen levels. 
After the addition of HCG serum testosterone rose 
rapidly from 7.8 to 17.4 nmol/1 within 24 hours. 
This further supported a diagnosis of ovarian hyper-
androgenism. Pelvic MRI showed bilateral poly-
cystic ovaries, without evidence of a separate 
ovarian tumor. The data were found to be consis-
tent with a diagnosis of PCOS. Venous sampling to 
rule out a small unilateral ovarian tumor was not 
performed because the additional information 
provided by this procedure would not outweigh the 
risks of hemorrhage or infarction that might occur. 
The patient was started on metformin 500 mg twice 
daily. Amenorrhea persisted despite continued 
treatment for 6 months. Therefore, it was decided to 
add the oral contraceptive Microgynon 50® 
(ethinylestradiol 50 μg and levonorgestrel 125 μg) 
in combination with cyproterone acetate 50 mg 
during the first 10 days of the cycle. This treatment 
was continued for one year and led to a decrease in 
serum testosterone from 9.1 to 3.3 nmol/1 and a 
lowering of the Ferriman-Gallwey score from 15 to 
6 (normal <8). 
DISCUSSION 
The present report suggests that the Cetrorelix 
suppression test may be useful in the diagnostic 
work-up of severe androgen excess in adolescence. 
Recently, it has been used successfully to assess the 
source of androgen excess in a postmenopausal 
woman". In contrast to its marked LH suppressive 
effects in postmenopause, a once daily injection of 
Cetrorelix 250 μg was insufficient to achieve ade-
quate LH suppression in adolescence. Twice daily 
injection improved LH and testosterone suppres-
sion, but did not completely normalize serum 
testosterone. The results suggest that higher doses 
or more frequent injections are required. 
Pilot studies designed to assess the optimal dose 
to prevent premature LH surges in women under-
going COH provide useful information regarding 
the dose necessary to obtain LH suppression of the 
degree required for diagnostic purposes1246 
Endogenous LH surges can be prevented by a 
single dose of Cetrorelix 5 mg, injected sub-
cutaneously on the ninth day of the cycle. This 
decreased serum LH within 24 hours from 5.5 ± 1.9 
to 0.2 ± 0.04 U/l, and the suppression lasted 5 
days12. Daily subcutaneous injection of Cetrorelix 1 
mg, starting on the 7th day of the cycle, reduced 
serum LH to a mean of 1 U/l13. In a study designed 
to assess the minimal effective dose to prevent 
premature LH surges, daily doses ranging from 
100-500 μg were tested14. Doses of 100 μg were 
not effective. Daily administration of Cetrorelix 
250 μg and 500 μg both succeeded in suppressing 
endogenous LH surges; however, after the adminis-
tration of 250 μg a minor increase in serum LH was 
observed 12 hours after injection. In our patient the 
once daily dose of 250 μg was associated with an 
LH escape of about 3 U/l above the preceding nadir 
value. This was considerable greater than the LH 
escape of 1 U/l in healthy women undergoing COH. 
The higher dose requirement for complete LH 
suppression in our patient could be related to 
altered LH secretion dynamics in patients with 
PCOS, or by age related differences in GnRH 
secretion. In adolescent females the GnRH pulse 
generator may be stronger than in females aged 20-
40 years, which would explain the higher dose of 
Cetrorelix to antagonize endogenous GnRH. In 
patients with PCOS serum LH levels are relatively 
high due to an increase in LH pulse frequency and 
amplitude, caused either by increased hypothalamic 
secretion of GnRH, increased pituitary sensitivity to 
GnRH, or both ' ' . Hayes et al. compared the 
effects of a first generation GnRH antagonist on 
serum LH levels in patients with PCOS and normal 
women and found that post-suppression LH levels 
were 5-6 U/l in adult women with PCOS and 2-3 
U/l in normal adult women15. Comparable results 
were obtained by Apter et al. who evaluated LH 
suppression in hirsute adolescent girls and develop-
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mentally matched controls16. We therefore con-
clude that patients with PCOS require relatively 
high doses of GnRH antagonists to obtain maximal 
LH suppression. We speculate that Cetrorelix 500 
μg twice daily will be sufficient to suppress LH 
below 2 mU/1 in adolescence. 
In conclusion, the Cetrorelix suppression test 
may become a useful instrument in the differential 
diagnosis of severe hyperandrogenemia of adoles-
cence and early adulthood, provided that the dose to 
achieve maximal suppression of LH and testos-
terone is more exactly defined. As a diagnostic 
agent, GnRH antagonists offer several advantages 
compared to GnRH agonists17. The desired hor-
monal responses occur more rapidly, are readily 
reversible and are not accompanied by hot flashes 
or other clinically relevant side effects. 
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